AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26125194
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) using fentanyl
Trial: 16771939
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (250 mg)
Trial: 14607452
Drug: TEE-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEE-guided treatment
Trial: 10997674
Drug: No Parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Parenteral Nutrition (no PN)
Trial: 19807
Drug: Naloxone 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 1.2 mg
Trial: 30290769
Drug: Antihelminthic drugs
RxNorm normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihelminthic drugs
Trial: 12505955
Drug: Jet with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet with 0.5 mL of lidocaine 1%
Trial: 12505955
Drug: Jet with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet with 0.5 mL of lidocaine 2%
Trial: 12505955
Drug: Jet with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet with 0.5 mL of saline
Trial: 7751490
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support treatment
Trial: 7751490
Drug: Self-control treatment
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-control treatment
Trial: 322546
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 20 mg
Trial: 322546
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 5 mg
Trial: 322546
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 10 mg
Trial: 25972490
Drug: THC 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 1.5 mg three times daily for 3 weeks
Trial: 25972490
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 3 weeks
Trial: 25752889
Drug: THC 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 1.5 mg
Trial: 16408462
Drug: Antihyperglycemic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihyperglycemic agent treatment
Trial: 9739438
Drug: 5‐FU 425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 425 mg/m2 given by bolus injection on days 1‐5 plus intravenous (i.v.) LV 20 mg/m2 every four to five weeks
Trial: 9739438
Drug: 5‐FU 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 3.5 g/m2/week in a 48‐hour continuous infusion
Trial: 7994260
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) administration during and after autologous bone marrow transplantation (BMT)
Trial: 2920496
Drug: Levodopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (250 mg) with Ferrous sulfate (325 mg)
Trial: 2920496
Drug: Levodopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (250 mg) without Ferrous sulfate (325 mg)
Trial: 25065293
Drug: FEC-D chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-D chemotherapy
Trial: 25065293
Drug: Standard anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anthracycline-based chemotherapy
Trial: 16579083
Drug: No. 2
RxNorm normalized name: K-Phos No. 2
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No. 2 Qu Feng Shi Ling capsules and Fenbid
Trial: 16579083
Drug: Lei Gong
RxNorm normalized name: mAb Hu3S193 - Anti-LeY
DrugBank: hu3S193 (DB17213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lei Gong Teng Tablets and Fenbid
Trial: 7655378
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (4800-6000 mg/m2) and carboplatin (1200-1800 mg/m2) followed by autologous bone marrow or peripheral blood stem cell infusion
Trial: 7655378
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide and carboplatin regimen
Trial: 23564922
Drug: Glucagon-like peptide
RxNorm normalized name: Glucagon-like peptide 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide 1 (GLP-1) infusion
Trial: 21864370
Drug: PEPS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEPS therapy plus treatment as usual (TAU)
Trial: 21864370
Drug: PEPS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEPS therapy plus TAU
Trial: 20046538
Drug: Screening, brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening, brief intervention and referral to treatment (SBIRT)
Trial: 17084787
Drug: Cognitive‐Behavioral Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Coping Skills Therapy
Trial: 15605326
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without exercise program (control group)
Trial: 11287029
Drug: DMPA+E(2)C injection
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA+E(2)C injection on day 7 of the menstrual cycle (delayed-injection group, n = 117)
Trial: 11287029
Drug: DMPA+E(2)C injection
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA+E(2)C injection on day 5 of the menstrual cycle (control group, n = 41)
Trial: 9311402
Drug: Hypnosis (audio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (audio tape daily 4-6 days prior to surgery)
Trial: 8455803
Drug: Marine fish-oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine fish-oil supplements rich in n-3 fatty acids
Trial: 8455803
Drug: Marine fish-oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine fish-oil supplements
Trial: 25739829
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m²/week for 4 weeks) with glucocorticoids and two intravenous cyclophosphamide pulses
Trial: 25739829
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide for 3-6 months followed by azathioprine with glucocorticoids (Control group)
Trial: 22706617
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch (5 μg/h)
Trial: 22167031
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (10 mg in 20 ml of fruit juice)
Trial: 22167031
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml of fruit juice)
Trial: 10901839
Drug: Clobazam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (30 mg daily)
Trial: 10901839
Drug: Lorazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (3 mg daily)
Trial: 10901839
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg daily)
Trial: 1511768
Drug: Medical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical intervention (colposcopy examination or outpatient ablative treatment)
Trial: 6140167
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-AS) 0.5 g suppositories
Trial: 6140167
Drug: Sulphasalazine (SZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (SZ) 1 g tid (equivalent to 5-AS 1.14 g/day)
Trial: 6140167
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release form of 5-AS
Trial: 16923481
Drug: Active patch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patch (GTN)
Trial: 15504999
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (handheld infrared skin thermometer, measuring temperatures on the sole of the foot in the morning and evening)
Trial: 15504999
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (therapeutic footwear, diabetic foot education, regular foot evaluation by a podiatrist)
Trial: 12243704
Drug: Hydrocolloid dressing
RxNorm normalized name: hydrocolloid dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dressing (HCD) over clobetasol propionate 0.05% lotion once a week
Trial: 12243704
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate ointment used unoccluded twice a day
Trial: 8327414
Drug: Aerosol inhaler
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhaler (active bronchodilator or placebo)
Trial: 8327414
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum as an adjunct to the behavioral program
Trial: 19374071
Drug: African potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: African potato (AP) decoction administered daily from day 16 to day 30
Trial: 12719963
Drug: Nutritionally-sourced tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutritionally-sourced tryptophan (1.8 g)
Trial: 10320169
Drug: Midazolam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.04 mg/kg) IV
Trial: 29668535
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose oral cholecalciferol over 2 years
Trial: 18330460
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT), 8 sessions
Trial: 15839956
Drug: Paclitaxel-platinum combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-platinum combination therapy
Trial: 15839956
Drug: Conventional platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional platinum-based therapy
Trial: 12209102
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with HDM-impermeable encasings for mattresses, pillows, and duvets for 12 months.
Trial: 12209102
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with cotton encasings for mattresses, pillows, and duvets for 12 months.
Trial: 10496190
Drug: Enalapril therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril therapy in white patients
Trial: 10496190
Drug: Enalapril therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril therapy in white patients with a history of hypertension
Trial: 9191512
Drug: Perindopril 8
RxNorm normalized name: perindopril 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 8 mg
Trial: 3030387
Drug: Perindopril 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 16 mg
Trial: 6344038
Drug: Zomepirac sodium
RxNorm normalized name: zomepirac sodium
DrugBank: Zomepirac (DB04828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac sodium 100 mg
Trial: 6587296
Drug: Fenoprofen calcium
RxNorm normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenoprofen calcium 200 mg
Trial: 30882751
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 × 200 mg elemental iron (SINGLE)
Trial: 30882751
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose of 2 × 100 mg elemental iron (SPLIT)
Trial: 22712470
Drug: Tretinoin microsphere
RxNorm normalized name: tretinoin microsphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin microsphere gel 0.04% pump
Trial: 17636093
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise with bright light treatment
Trial: 17636093
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise without bright light treatment
Trial: 16118756
Drug: Hip head-conserving
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip head-conserving therapy with two cranial screws and a three-point-supported screw at Adam's arc
Trial: 7567130
Drug: Ceftriaxone 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia
Trial: 7567130
Drug: Ceftriaxone 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1,000 mg intravenously before anesthesia and a second 1,000 mg dose at the initiation of cardiopulmonary bypass
Trial: 7567130
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (1,000 mg and 2,000 mg regimens)
Trial: 2127604
Drug: hMG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG treatment with short-term GnRH agonist (Buserelin)
Trial: 2127604
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with hMG alone
Trial: 2127604
Drug: hMG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG treatment started shortly after LH rise caused by GnRH agonist
Trial: 2127604
Drug: hMG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG treatment commenced when hypogonadotropic state achieved after long treatment of Buserelin
Trial: 2127604
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (hMG with and without GnRH agonist)
Trial: 21849007
Drug: Sitagliptin (SITA)
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin (SITA) 100 mg qd
Trial: 31802616
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 850 mg bid
Trial: 31802616
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Sitagliptin (MET+SITA) 50 + 850 mg bid
Trial: 31471037
Drug: Losartan (LT)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan (LT) 50 mg
Trial: 29948456
Drug: Combined 660-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 660- and 808-nm wavelengths low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Trial: 29948456
Drug: 660-nm wavelength
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660-nm wavelength low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Trial: 25187257
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (vitamin C) 10 mg/kg/day and α-tocopherol (vitamin E) 10 mg/kg/day
Trial: 22342027
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral self-help program (SHP) combined with pharmacotherapy
Trial: 22342027
Drug: Pharmacotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy alone (control)
Trial: 20228402
Drug: Nateglinide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (up to 60 mg three times daily)
Trial: 15797672
Drug: Calcium pyruvate
RxNorm normalized name: Calcium pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium pyruvate (PYR) 5 g twice daily for 30 days
Trial: 9927844
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (t-PA)
Trial: 2669554
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms
Trial: 2669554
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms
Trial: 2669554
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (BUD) 400 micrograms
Trial: 2669554
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (BUD) 800 micrograms
Trial: 365774
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose subunit vaccine (2100 IU)
Trial: 947849
Drug: Whole virus
RxNorm normalized name: rabies, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole virus vaccine (2100 IU)
Trial: 365774
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose subunit vaccine (700 IU)
Trial: 365774
Drug: Split virus
RxNorm normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split virus adjuvant vaccine (800 IU with AI(OH)3)
Trial: 30580896
Drug: Stereoscopic 3D
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereoscopic 3D immersive video exposure-based treatment (six 5-minute exposures)
Trial: 16455419
Drug: Ultrasound contrast
RxNorm normalized name: ULTRASOUND CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound contrast agent (UCA) Optison
Trial: 16455419
Drug: Contrast agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agents (Optison, Sonovue, Sonazoid)
Trial: 15762255
Drug: Other cemented
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other cemented implants
Trial: 8214276
Drug: mefloquine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefloquine treatment
Trial: 3593451
Drug: Terguride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terguride (2 X 0.2 mg/d per os)
Trial: 24655769
Drug: Group-based counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based counselling intervention for depression adapted from Interpersonal Therapy (IPT)
Trial: 19730952
Drug: Single-dose Stretta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose Stretta (Group A)
Trial: 19730952
Drug: Double-dose Stretta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose Stretta (Group C)
Trial: 9203723
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) at 4 and 9 months of age
Trial: 8291408
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg 3 times daily for 2 weeks
Trial: 24839241
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5mg yearly infusion
Trial: 22153327
Drug: Contemporary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contemporary treatment or task-specific training
Trial: 20505273
Drug: Orbital lesion
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital lesion and oral cavity lesion
Trial: 20505273
Drug: Bilateral orbital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral orbital lesions, buccal, rectum, and stomach lesions
Trial: 17490954
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) at a dose of 3.2 g/d
Trial: 16308498
Drug: CC-guided PV
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-guided PV isolation
Trial: 25361685
Drug: Self-reported medication
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported medication non-adherence
Trial: 23183356
Drug: Tyrothricin 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrothricin 0.1% gel
Trial: 21450978
Drug: AS03(A)‐adjuvanted H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)‐adjuvanted H1N1 vaccine containing 3.75 μg hemagglutinin (HA)